Research Article
Beta-Thalassemia Intermedia: A Single Thalassemia Center Experience from Northeastern Iraq
Table 6
Relations of different parameters in all genotype groups.
| Parameters | β0/β0 (%) | β0/β+ (%) | β+/β+ (%) | Dominant Hb Houston/wt | β+/wt (%) | β0/wt (%) | value |
| Age at diagnosis | | | | | | | | | | | | 10 | | | 0.019 | Age at first transfusion | | | | | | | | | | | 8 | | | 0.020 | Transfusion | | | | | | | | No | 19 (21.3) | 5 (18.5) | 9 (23.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.900 | Yes | 70 (78.7) | 22 (81.5) | 29 (76.3) | 1 (100.0) | 2 (100.0) | 2 (100.0) | Iron chelation | | | | | | | | No | 48 (53.9) | 19 (70.4) | 28 (73.7) | 0 (0.0) | 0 (0.0) | 1 (50.0) | 0.071 | Yes | 41 (46.1) | 8 (29.6) | 10 (26.3) | 1 (100.0) | 2 (100.0) | 1 (50.0) | Hb A2 % | | | | | | | | <3.5 | 52 (92.9) | 14 (73.7) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | <0.0001 | ≥3.5 | 4 (7.1) | 5 (26.3) | 26 (89.7) | 1 (100.0) | 1 (100.0) | 2 (100.0) | Hb F % | | | | | | | | <50 | 4 (6.9) | 3 (15.8) | 26 (89.7) | 1 (100.0) | 1 (100.0) | 2 (100.0) | <0.0001 | ≥50 | 54 (93.1) | 16 (84.2) | 3 (10.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | Splenectomy | | | | | | | | No | 55 (62.5) | 21 (77.8) | 27 (73.0) | 0 (0.0) | 0 (0.0) | 2 (100.0) | 0.079 | Yes | 33 (37.5) | 6 (22.2) | 10 (27.0) | 1 (100.0) | 2 (100.0) | 0 (0.0) | PHT | | | | | | | | No | 77 (86.5) | 23 (85.2) | 37 (97.4) | 0 (0.00 | 2 (100.0) | 2 (100.0) | 0.036 | Yes | 12 (13.5) | 4 (14.8) | 1 (2.6) | 1 (100.0) | 0 (0.0) | 0 (0.0) | Hepatomegaly | | | | | | | | No | 51 (57.3) | 18 (66.7) | 27 (71.1) | 1 (100.0) | 1 (50.0) | 1 (50.0) | 0.659 | Yes | 38 (42.7) | 9 (33.3) | 11 (28.9) | 0 (0.0) | 1 (50.0) | 1 (50.0) | Hepatitis C | | | | | | | | No | 77 (86.5) | 25 (92.1) | 35 (92.1) | 0 (0.0) | 2 (100.0) | 2 (100.0) | 0.087 | Yes | 12 (13.5) | 2 (7.4) | 3 (7.9) | 1 (100.0) | 0 (0.0) | 0 (0.0) | Osteoporosis | | | | | | | | No | 21 (61.8) | 10 (90.9) | 10(83.3) | 1 (100.0) | 1 (50.0) | — | 0.257 | Yes | 13 (38.2) | 1 (9.1) | 2 (16.7) | 0 (0.0) | 1 (50.0) | — | Cholelithiasis | | | | | | | | No | 78 (87.6) | 25 (92.6) | 32 (84.2) | 1 (100.0) | 2 (100.0) | 2 (100.0) | 0.882 | Yes | 11 (12.4) | 2 (7.4) | 6 (15.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | Hypothyroidism | | | | | | | | No | 67 (87.0) | 18 (72.0) | 31 (86.1) | 1 (100.0) | 2 (100.0) | 2 (100.0) | 0.349 | Yes | 10 (13.0) | 7 (28.0) | 5 (13.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) | Growth retardation | | | | | | | | No | 31 (60.8) | 17 (89.5) | 16 (84.2) | — | — | 1 (100.0) | 0.323 | Yes | 20 (39.2) | 2 (10.5) | 3 (15.8) | — | — | 0 (0.0) | ALT | | | | | | | | ≤50 | 81 (91.0) | 24 (88.9) | 37 (97.4) | 1 (100.0) | 2 (100.0) | 2 (100.0) | 0.779 | >50 | 8 (9.0) | 3 (11.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | S. ferritin | | | | | | | | <1000 | 65 (74.7) | 22 (81.5) | 31 (83.) | 1 (100.0) | 1 (50.0) | 2 (100.0) | 0.663 | ≥1000 | 22 (25.3) | 5 (18.5) | 6 (16.2) | 0 (0.0) | 1 (50.0) | 0 (0.0) | Facial deformity | | | | | | | | No | 22 (24.7) | 13 (48.1) | 22 (57.9) | 1 (100.0) | 0 (0.0) | 2 (100.0) | 0.001 | Yes | 67 (75.3) | 14 (51.9) | 16 (42.1) | 0 (0.0) | 2 (100.0) | 0 (0.0) |
|
|